Mslp, Orex, Mpel On Pennytobuck Stock Updates
MusclePharm Corporation (OTCBB:MSLP.OB), one of the fastest growing nutritional supplement
companies in the United States with a proprietary formulation used in eight performance products, has announced MuscleGel achieves NSF certification. In addition, the Companys Recon and Assault nutritional products will be NSF certified within the coming months.
MSLP declared the appointment of Mariel Selbovitz, MPH, as Director of Global Therapeutics Product Procurement Development. Ms. Selbovitz is a graduate of Cornell University and received her Masters in Public Health at the Johns Hopkins University Bloomberg School of Health. She worked as the Client Intake Specialist at Positive Health Project and Syringe Exchange Program Coordinator at the Foundation for Research on Sexually Transmitted Diseases and is a partner in BioEquity Partners
Selbovitz is also a member of the Cornell AIDS Clinical Trials Group Community Advisory Board and AIDS Treatment Advocacy Coalition. She presented at the 5th European Conference on Clinical and Social Research on AIDS and Drugs, International Conference on Antiviral Research, 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention and XVIII International AIDS Conference.
MSLP products are currently available in 1,200 of the top General Nutrition Centers (GNC) in the United States, as well as Vitamin Shop. MusclePharms award-winning products Assault, Battle Fuel, Bullet Proof, Combat Powder, Recon and Shred Matrixare also available online at gnc.com, bodybuilding.com, amazon.com and many other locations.
Melco Crown Entertainment Limited (Nasdaq:MPEL), a developer and owner of casino gaming and entertainment resort facilities focused on the Macau market, announced recently that following a discussion with Simon Dewhurst, he tendered his resignation from his position as EVP and Chief Financial Officer. We thank Simon for his past support and contributions to Melco Crown Entertainment.
To ensure a seamless transition, Leanne Palmer, currently Vice President, Financial Compliance for MPEL, has assumed the role of acting CFO in the interim period, while MPEL conducts a global search for a suitable candidate with exceptional caliber to fill the CFO position.
Additionally, Geoffrey Davis, CFA, has been promoted to Deputy CFO and Treasurer on a permanent basis and will be based in Macau. Prior to joining Melco Crown Entertainment as Senior Vice President, Corporate Finance in 2007, he was the lead equity research analyst at Citi Investment Research covering the gaming industry. He had previously been Vice President, Corporate Finance for Park Place Entertainment in Las Vegas.
Melco Crown Entertainment Limited , is a developer, owner and through a Macau subsidiary which holds a gaming sub-concession, an operator of casino gaming and entertainment casino resort facilities. MPEL currently operates Altira Macau (www.altiramacau.com) (formerly Crown Macau), a casino hotel located at Taipa, Macau and City of Dreams (www.cityofdreamsmacau.com), an integrated urban casino resort located in Cotai, Macau. MPELs business also includes the Mocha Clubs (www.mochaclubs.com), which feature a total of approximately 1,500 gaming machines in eight locations and comprise the largest non-casino based operations of electronic gaming machines in Macau.
Orexigen Therapeutics Inc., OREX
Orexigen Therapeutics Inc., (Nasdaq:OREX) took the spotlight early Thursday as shares of the biotech group soared as they signed a North American partnership for its experimental obesity drug Contrave with Takeda Pharmaceutical Co. for $50 million and the potential for later payments that could exceed $1 billion.
Under the terms of the deal, Takeda will market the product in the U.S., Mexico and Canada upon approval. Orexigen will receive $50 million up front and is eligible for more than $1 billion in various milestone payments. Orexigen will also receive tiered double-digit royalties on sales.
Orexigen expects to receive a decision from the U.S. Food and Drug Administration on Contrave by Jan. 31, 2011.
Contrave is one of three new diet drugs up for FDA approval.
Orexigen Therapeutics, Inc., a biopharmaceutical company, focuses on the development of pharmaceutical product candidates for the treatment of obesity. Its lead combination product candidates include Contrave, which has completed Phase III clinical trials; and Empatic that has completed Phase II clinical trials. Contrave is a combination of two drugs, bupropion and naltrexone, in a sustained release formulation (SR). Bupropion is an antidepressant and smoking cessation medication; naltrexone is a treatment for alcohol and opioid addiction. The companys Empatic product candidate is a combination of bupropion SR and zonisamide SR. Zonisamide, in an immediate release formulation for the adjunctive treatment of partial seizures, a form of epilepsy. The company was founded in 2002 and is based in La Jolla, California.
For FREE Daily Stock Alerts & Updates Signup At: http://pennytobuck.com/signup
THIS IS NOT A RECOMMENDATION TO BUY OR SELL ANY SECURITY!
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. PennyToBuck.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers.Our disclaimer ( http://pennytobuck.com/disclaimer) is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold PennyToBuck.com report and Crown Equity Holdings Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings Inc. (CRWE.OB) is a newswire as well as an IR and PR firm. Crown Equity Holdings Inc. (CRWE.OB), in some cases, provides media advertising and public awareness for both public and private companies, as well as disseminating news. As such, in some cases, when Crown Equity Holdings Inc. (CRWE.OB) advertises for a particular client, Crown Equity Holdings Inc. (CRWE.OB) charges an advertising fee which it must disclose under 17B. The fee may be in cash, in free trading stock or in restricted stock. Crown Equity Holdings Inc. (CRWE.OB), if paid in stock, can and may sell those securities during the advertising period. Crown Equity Holdings Inc. (CRWE.OB) has received twenty five thousand dollars in cash and twenty five thousand dollars in free trading stock from a third party (Bishop Equity Partners) for (30) days of advertising for Muscle Pharm Corp. (MSLP.OB).
by: Bill Pennyman
Stock Update On Crwe, Rnin And Eqlb From Pennytobuck.com Orfg, Eqlb And Mmr On Pennytobucks Stock Highlights For September 7th, 2010. Stocks On The Pennytobuck Highlight Include Eqlb, Kore And Uwn Climb For A Cause's "Peak Performers" Smash All Previous Fundraising Records 7 Signs That Someone Is Attracted To You And That They Like You The Pros And Cons Of Argireline Boston Fans and Players Alike Enjoy HD Maximum Earnings And How To Avoid ' Smart Pricing ' Beekeeping and Understanding the Bee Hive Herniation: Definition, Pathophysiology and Clinical Dog Carts And Their Features The Number Of Battery Charging And Discharging Is Limited Smart Stock Trading Suggestions